Experimental groups
Mice were randomly divided into the following groups (n = 10 for each group):
• Sham + vehicle group: vehicle solution (carboxymethylcellulose 1.5% wt/vol in saline) was administered orally for 28 days.
• Sham + PEA-MPS group: mice were treated orally daily with 10 mg/Kg PEA-MPS (300 mg PEAm and 600 mg PEA-um1) for 28 days.
• Fracture + vehicle group: vehicle solution (carboxymethylcellulose 1.5% wt/vol in saline) was administered orally daily 1 h after surgery for 28 days.
• Fracture + PEA-MPS group: mice were treated orally daily with 10 mg/Kg PEA-MPS (300 mg PEAm and 600 mg PEA-um1) 1 h after surgery for 28 days.
The dose of PEA-MPS was chosen based on previous experiments ( [2] ; reference 23 in the original publication).
In the previous study ( [2] ; reference 23 in the original publication), we have demonstrated the beneficial effects of PEA in reducing edema formation and thermal hyperalgesia in carrageenan-induced inflammation in the rat paw. These results show the differential effects exerted on the degree of inflammation by micronized PEA-m and ultramicronized PEA-um, vs nonmicronized PeaPure.
We have done the calculation to know the dose of PEA-MPS that should be assumed by a human. According to the formula applied for the conversion from animal to human, the dose of PEA-MPS that should be taken would be about 48,6 mg for a 60 Kg human. Human Equivalent Dose PEA-MPS (mg/kg) = (10x[3/37]) = 0,81 mg/Kg, thus, for a 60 Kg human, the dose is 48,6 mg.
The minimum number of animals for each group was calculated using the statistical test a priori power analyzes of the G-power software. This statistical test provides an efficient method for determining the sample size necessary to perform the experiment before the experiment the same is actually conducted.
In addition, the primary data underlying quantitative results were not included with the published article. The primary data are included below in S1 File.
